9 research outputs found
Glyceria ?nerva (Nerved Manner Grass) : Nerved Manner Grass
No full textClass: Monocotyledoneae
Family: Poaceae
Genus: Glyceria
Species: ?nerv
Context-aware services bundling for motorcycle police officers - The design of a business model offering context-aware service bundling to increase value for motorcycle police officers
No full textTechnology, Policy and Managemen
Sporobolous cryptandrus (Sand Dropseed) : Sand Dropseed
No full textClass: Monocotyledoneae
Family: Poaceae
Genus: Sporobolous
Species: cryptandru
Utilization pattern of mineralocorticoid receptor antagonists in contemporary patients hospitalized with acute decompensated heart failure: A single-center experience
No full textBackground Recent studies have broadened the potential use of mineralocorticoid receptor antagonist (MRA) in patients with systolic heart failure after cardiovascular hospitalization. Real-world data on safety and tolerability of MRA initiation during hospitalization for acute decompensated heart failure (ADHF) are lacking. We examined the patterns of utilization of MRAs in patients admitted for ADHF in contemporary clinical practice. Methods and Results We reviewed consecutive hospitalized patients admitted with a primary diagnosis of ADHF from March to June 2011. The treatment patterns of MRA use or discontinuation before, during, and after hospitalization were reviewed and analyzed retrospectively. In the study cohort of 500 patients, 106 patients (21percent) were on MRAs before admission. During hospitalization, preadmission and newly started MRAs were discontinued in 64 out of 177 (36percent), with worsening renal function being the most common identifiable reason. In a multivariate analysis, high admission creatinine was the only significant predictor of MRA discontinuation during hospitalization (P =.01). Of the 394 patients who did not receive MRA before admission, 81 were eligible for MRAs, but only 17 (21percent) were initiated. After a median follow up of 57 days, 21 additional patients discontinued MRAs; of 72 eligible patients for MRA, 55 patients (76percent) were still appropriately taking it. Conclusions Despite recent data, MRAs are still underutilized in patients admitted with ADHF who are otherwise eligible for it. Elevated serum creatinine and worsening of renal function are the most common cause of in-hospital discontinuation, which highlights the importance of meticulous follow-up after MRA initiation. © 2014 Elsevier Inc. All rights reserved.Albert NM, 2009, JAMA-J AM MED ASSOC, V302, P1658, DOI 10.1001-jama.2009.1493; Butler J, 2012, J CARD FAIL, V18, P265, DOI 10.1016-j.cardfail.2012.02.005; Eschalier R, 2013, J AM COLL CARDIOL, V62, P1585, DOI 10.1016-j.jacc.2013.04.086; Ferreira JP, 2014, EUR J INTERN MED, V25, P67, DOI 10.1016-j.ejim.2013.08.711; Goebel Jason A, 2008, Curr Heart Fail Rep, V5, P153, DOI 10.1007-s11897-008-0024-y; Hamaguchi S, 2010, AM HEART J, V160, P1156, DOI 10.1016-j.ahj.2010.08.036; Hernandez AF, 2012, JAMA-J AM MED ASSOC, V308, P2097, DOI 10.1001-jama.2012.14795; Jacob Miriam S, 2011, Curr Heart Fail Rep, V8, P7, DOI 10.1007-s11897-010-0046-0; Krantz MJ, 2011, AM J CARDIOL, V107, P1818, DOI 10.1016-j.amjcard.2011.02.322; Maron BA, 2010, CIRCULATION, V121, P934, DOI 10.1161-CIRCULATIONAHA.109.895235; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056-NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056-NEJM199909023411001; Testani JM, 2010, CIRCULATION, V122, P265, DOI 10.1161-CIRCULATIONAHA.109.933275; Testani JM, 2011, CIRC-HEART FAIL, V4, P685, DOI 10.1161-CIRCHEARTFAILURE.111.963256; Vardeny O, 2012, J AM COLL CARDIOL, V60, P2082, DOI 10.1016-j.jacc.2012.07.048; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016-j.jacc.2013.05.019; Zannad F, 2011, NEW ENGL J MED, V364, P11, DOI 10.1056-NEJMoa10094923
Factors Influencing Enterprise Resource Planning System: A Review
Full text linkThe purpose of this paper is to provide a comprehensive review on factors that influence the enterprise resource planning system (ERP-S) implementation from literature studies between 2011 and 2016. A set of criteria was set to explore ERP-S related research articles through academic search engines and academic databases. Selected articles were categorized into critical success failure factors (CSFF), ERP-S user factors, and ERP-S assimilation factors. The findings from this paper provides a deeper understanding to both academicians and industrial practitioners regarding ERP-S success factors. A strategic plan can also be developed to ensure successful ERP-S implementation
Application of AHP on SMED for Jig and Fixture Design Selection
Full text linkThe purpose of this paper is to discuss the application of AHP as decision-making tool in determining best design model. Three design models had been developed were based on SMED concept which significant with small manufacturing enterprise jig and fixtures engineering project. For analysis, 10 design requirements were considered and used in AHP analysis. The result shows that there are four parameters were agreed as critical measures including gripping, ease of assembly, ease of cleaning and go-no-go inspection, meanwhile easy maintenance was less important for SMED product
Prognostic role of pulmonary arterial capacitance in advanced heart failure
No full textBackground-Right ventricular (RV) dysfunction frequently occurs and independently prognosticates in left-sided heart failure. It is not clear which RV afterload measure has the greatest impact on RV function and prognosis. We examined the determinants, prognostic role, and response to treatment of pulmonary arterial capacitance (PAC, ratio of stroke volume over pulmonary pulse pressure), in relation to pulmonary vascular resistance (PVR) in heart failure. Methods and Results-We reviewed 724 consecutive patients with heart failure who underwent right heart catheterization between 2000 and 2005. Changes in PAC were explored in an independent cohort of 75 subjects treated for acute decompensated heart failure. PAC showed a strong inverse relation with PVR (r=-0.64) and wedge pressure (r=-0.73), and provides stronger prediction of significant RV failure than PVR (area under the curve ROC 0.74 versus 0.67, respectively, P=0.003). During a mean follow-up of 3.2±2.2 years, both lower PAC (P0.0001) and higher PVR (P0.0001) portend more adverse clinical events (all-cause mortality and cardiac transplantation). In multivariate analysis, PAC (but not PVR) remains an independent predictor (Hazard ratio=0.92 [95percent CI: 0.84-1.0, P=0.037]). Treatment of heart failure resulted in a decrease in PVR (270±165 to 211±88 dynes.s-1.cm-5, P=0.002), a larger increase in PAC (1.65±0.64 to 2.61±1.42 mL-mm Hg, P0.0001), leading to an increase in pulmonary arterial time constant (PVR×PAC) (0.29±0.12 to 0.37±0.15 second, P0.0001). Conclusions-PAC bundles the effects of PVR and left-sided filling pressures on RV afterload, explaining its strong relation with RV dysfunction, poor long-term prognosis, and response to therapy. © 2012 American Heart Association, Inc.Aronson D, 2011, CIRC-HEART FAIL, V4, P644, DOI 10.1161-CIRCHEARTFAILURE.110.960864; BAKER BJ, 1984, AM J CARDIOL, V54, P596, DOI 10.1016-0002-9149(84)90256-X; Bonderman D, 2011, CHEST, V139, P122, DOI 10.1378-chest.10-0348; Butler J, 1999, J AM COLL CARDIOL, V34, P1802, DOI 10.1016-S0735-1097(99)00408-8; de Groote P, 1998, J AM COLL CARDIOL, V32, P948, DOI 10.1016-S0735-1097(98)00337-4; de Perrot M, 2011, CHEST, V140, P34, DOI 10.1378-chest.10-1263; DISALVO TG, 1995, J AM COLL CARDIOL, V25, P1143, DOI 10.1016-0735-1097(94)00511-N; Ghio S, 2001, J AM COLL CARDIOL, V37, P183, DOI 10.1016-S0735-1097(00)01102-5; HARRIS P, 1965, BRIT HEART J, V27, P651; Juilliere Y, 1997, EUR HEART J, V18, P276; Karatasakis GT, 1998, AM J CARDIOL, V82, P329, DOI 10.1016-S0002-9149(98)00344-0; Lankhaar JW, 2006, AM J PHYSIOL-HEART C, V291, pH1731, DOI 10.1152-ajpheart.00336.2006; Lankhaar JW, 2008, EUR HEART J, V29, P1688, DOI 10.1093-eurheartj-ehn103; MACKAY EH, 1978, THORAX, V33, P335, DOI 10.1136-thx.33.3.335; Mahapatra S, 2006, J AM COLL CARDIOL, V47, P799, DOI 10.1016-j.jacc.2005.09.054; Mahapatra S, 2006, J AM SOC ECHOCARDIOG, V19, P1045, DOI 10.1016-j.echo.2006.03.008; POLAK JF, 1983, J AM COLL CARDIOL, V2, P217; Saouti N, 2009, AM J PHYSIOL-HEART C, V297, pH2154, DOI 10.1152-ajpheart.00694.2009; Tedford RJ, 2012, CIRCULATION, V125, P289, DOI 10.1161-CIRCULATIONAHA.111.051540; Voelkel NF, 2006, CIRCULATION, V114, P1883, DOI 10.1161-CIRCULATIONAHA.106.632208; WESTERHO.N, 1971, J APPL PHYSIOL, V31, P776; Westerhof N, 2009, MED BIOL ENG COMPUT, V47, P131, DOI 10.1007-s11517-008-0359-212
Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: State of the art review and focus on emerging nuclear techniques
No full textAmyloidosis is an infiltrative disease characterized by deposition of amyloid fibrils within the extracellular tissue of one or multiple organs. Involvement of the heart, cardiac amyloidosis, is recognized as a common cause of restrictive cardiomyopathy and heart failure. The two major types of cardiac amyloidosis are cardiac amyloid light-chain (AL) and transthyretin-related cardiac amyloidosis (ATTR, mutant and wild types) (Nat Rev Cardiol 2010;7:398-408). While early recognition of cardiac amyloidosis is of major clinical importance, so is the ability to differentiate between subtypes. Indeed, both prognosis and therapeutic options vary drastically depending on the subtype. While endomyocardial biopsy with immunostaining is considered the gold standard, advances in imaging provide an attractive non-invasive alternative. Currently, electrocardiography, echocardiography, and cardiac magnetic resonance imaging are all used in the evaluation of cardiac amyloidosis with varying diagnostic and prognostic accuracy. Yet, none of these modalities can effectively differentiate the cardiac amyloid subtypes. Recent data with 99mTc-phosphate derivatives, previously used as bone seeking radioactive tracers, have shown promising results; these radiotracers selectively bind ATTR, but not AL subtype, and can differentiate subtypes with high diagnostic accuracy. This review will initially present the non-radionuclide imaging techniques and then focus on the radionuclide imaging techniques, particularly 99mTc-DPD and 99mTc-PYP, mechanism of action, performance and interpretation of the study, diagnostic accuracy, prognostic value, future clinical perspective, and outlook. © 2013 American Society of Nuclear Cardiology.Antoni G, 2013, J NUCL MED, V54, P213, DOI 10.2967-jnumed.111.102053; Austin BA, 2009, JACC-CARDIOVASC IMAG, V2, P1369, DOI 10.1016-j.jcmg.2009.08.008; Austin BA, 2009, AM J CARDIOL, V103, P1429, DOI 10.1016-j.amjcard.2009.01.361; Banypersad SM, 2013, CIRC-CARDIOVASC IMAG, V6, P34, DOI 10.1161-CIRCIMAGING.112.978627; Bellavia D, 2008, AM J CARDIOL, V101, P1039, DOI 10.1016-j.amjcard.2007.11.047; Bellavia D, 2012, EUR HEART J-CARD IMG, V13, P680, DOI 10.1093-ehjci-jes009; Bellavia D, 2010, J AM SOC ECHOCARDIOG, V23, P643, DOI 10.1016-j.echo.2010.03.027; Benson MD, 2003, BEST PRACT RES CL RH, V17, P909, DOI 10.1016-j.berh.2003.09.001; Bokhari S, 2013, CIRC-CARDIOVASC IMAG, V6, P195, DOI 10.1161-CIRCIMAGING.112.000132; Buss SJ, 2012, J AM COLL CARDIOL, V60, P1067, DOI 10.1016-j.jacc.2012.04.043; Buxbaum J, 2010, AM HEART J, V159, P864, DOI 10.1016-j.ahj.2010.02.006; CARROLL JD, 1982, AM J CARDIOL, V49, P9, DOI 10.1016-0002-9149(82)90270-3; Chen WG, 2012, CURR CARDIOL REP, V14, P226, DOI 10.1007-s11886-011-0239-5; Cheng ZW, 2011, ANN NONINVAS ELECTRO, V16, P25, DOI 10.1111-j.1542-474X.2010.00403.x; Coelho T, 2013, NEW ENGL J MED, V369, P819, DOI 10.1056-NEJMoa1208760; Cooper LT, 2007, CIRCULATION, V116, P2216, DOI 10.1161-CIRCULATIONAHA.107.186093; Dubrey SW, 1998, QJM-MON J ASSOC PHYS, V91, P141, DOI 10.1093-qjmed-91.2.141; Dungu J, 2012, J AM COLL CARDIOL, V59, P1225; Dungu J, 2012, AM HEART J, V164, P72, DOI 10.1016-j.ahj.2012.04.013; Dungu JN, 2012, HEART, V98, P1546, DOI 10.1136-heartjnl-2012-301924; FALK RH, 1983, AM J CARDIOL, V51, P826, DOI 10.1016-S0002-9149(83)80140-4; Feng DL, 2009, CIRCULATION, V119, P2490, DOI 10.1161-CIRCULATIONAHA.108.785014; Furukawa K, 2012, CIRCULATION, V125, P556, DOI 10.1161-CIRCULATIONAHA.111.045237; GERTZ MA, 1987, ARCH INTERN MED, V147, P1039, DOI 10.1001-archinte.147.6.1039; Glaudemans AWJM, 2009, EUR J NUCL MED MOL I, V36, P702, DOI 10.1007-s00259-008-1037-1; Granstam SO, 2013, AMYLOID, V20, P27, DOI 10.3109-13506129.2012.761967; Hazenberg BPC, 2004, NETH J MED, V62, P121; Hongo M, 1985, J Cardiogr, V15, P163; Karamitsos TD, 2013, JACC-CARDIOVASC IMAG, V6, P488, DOI 10.1016-j.jcmg.2012.11.013; KLEIN AL, 1991, CIRCULATION, V83, P808; Koyama J, 2010, JACC-CARDIOVASC IMAG, V3, P333, DOI 10.1016-j.jcmg.2009.11.013; Koyama J, 2003, CIRCULATION, V107, P2446, DOI 10.1161-01.CIR.0000068313.67758.4F; Kristen AV, 2007, J HEART LUNG TRANSPL, V26, P1313, DOI 10.1016-j.healun.2007.09.014; Kyle RA, 1996, AM J MED, V101, P395, DOI 10.1016-S0002-9343(96)00229-X; Maceira AM, 2005, CIRCULATION, V111, P186, DOI 10.1161-01.CIR.0000152819.97857.9D; Mekinian A, 2010, AM J MED, V123, P864, DOI 10.1016-j.amjmed.2010.03.022; Minutoli F, 2013, AM J ROENTGENOL, V200, pW256, DOI 10.2214-AJR.12.8737; Mohty D, 2011, ARCH CARDIOVASC DIS, V104, P611, DOI 10.1016-j.acvd.2011.10.004; Mongeon FP, 2012, JACC-CARDIOVASC IMAG, V5, P897, DOI 10.1016-j.jcmg.2012.04.006; Murtagh B, 2005, AM J CARDIOL, V95, P535, DOI 10.1016-j.amjcard.2004.10.028; Mussinelli R, 2013, ANN NONINVAS ELECTRO, V18, P271, DOI 10.1111-anec.12036; Boldrini M, 2013, ANN NONINVAS ELECTRO, V18, P327, DOI 10.1111-anec.12032; Namdar M, 2012, AM J CARDIOL, V109, P587, DOI 10.1016-j.amjcard.2011.09.052; Ng B, 2005, ARCH INTERN MED, V165, P1425, DOI 10.1001-archinte.165.12.1425; Noordzij W, 2012, AMYLOID, V19, P208, DOI 10.3109-13506129.2012.717993; OLSON LJ, 1984, AM J CARDIOL, V53, P980, DOI 10.1016-0002-9149(84)90551-4; Pennell DJ, 2009, JACC-CARDIOVASC IMAG, V2, P1378, DOI 10.1016-j.jcmg.2009.10.001; PEPYS MB, 1979, CLIN EXP IMMUNOL, V38, P284; Perlini S, 2013, INT J CARDIOL, V167, P2156, DOI 10.1016-j.ijcard.2012.05.097; Perugini E, 2005, J AM COLL CARDIOL, V46, P1076, DOI 10.1016-j.jace.2005.05.073; Phelan D, 2012, HEART, V98, P1442, DOI 10.1136-heartjnl-2012-302353; Piper C, 2010, AMYLOID, V17, P1, DOI 10.3109-13506121003619310; Rapezzi C, 2011, EUR J NUCL MED MOL I, V38, P470, DOI 10.1007-s00259-010-1642-7; Rapezzi C, 2010, NAT REV CARDIOL, V7, P398, DOI 10.1038-nrcardio.2010.67; Rapezzi C, 2011, JACC-CARDIOVASC IMAG, V4, P659, DOI 10.1016-j.jcmg.2011.03.016; Reyners AKL, 2002, EUR HEART J, V23, P157, DOI 10.1053-euhj.2001.2972; Ruberg FL, 2012, AM HEART J, V164, P222, DOI 10.1016-j.ahj.2012.04.015; Ruberg FL, 2009, AM J CARDIOL, V103, P544, DOI 10.1016-j.amjcard.2008.09.105; Sattianayagam PT, 2012, EUR HEART J, V33, P1120, DOI 10.1093-eurheartj-ehr383; SIMONS M, 1992, AM J CARDIOL, V69, P425, DOI 10.1016-0002-9149(92)90250-3; SOBOL SM, 1982, AM HEART J, V103, P563, DOI 10.1016-0002-8703(82)90344-1; Syed IS, 2010, JACC-CARDIOVASC IMAG, V3, P155, DOI 10.1016-j.jcmg.2009.09.023; Tei CW, 1996, J AM COLL CARDIOL, V28, P658, DOI 10.1016-0735-1097(96)00202-1; Vrana JA, 2009, BLOOD, V114, P4957, DOI 10.1182-blood-2009-07-230722; Wassmuth R, 2011, EUR RADIOL, V21, P1643, DOI 10.1007-s00330-011-2109-3; Wells K, 2013, J NUCL MED, V54, P294; Westermark P, 2005, AMYLOID, V12, P1, DOI 10.1080-13506120500032196; Yamamoto Y, 2012, ANN NUCL MED, V26, P634, DOI 10.1007-s12149-012-0627-y14
ESUPPLIER APPROVAL PROCESS ON COMPOSITES’ PRODUCT-BASED MANUFACTURERS
Full text linkThe supplier is one of the keys to success in an organization and can also be the cause of the collapse of the company in which the supplier is able to introduce a number of problems such as supply of poor raw materials, shipping delays, poor services and failure to comply the requirement. Hence, approved supplier list has been used as a reference and a guide to the purchasing department to sourcing a trusted supplier. Therefore the development of process flow for approved supplier list must be done right for the effectiveness of this system. This paper analyzed supplier approval process on four selected companies specializing in composite product and manufacturing. The data collection consists of a series of semi-structured interview with supply chain personnel, documentation review and observation. These findings indicated that the same concept such as system audit, questionnaire and supplier assessment was used in a process of selecting potential suppliers prior to being inserted in the approved supplier list. Besides, the study identified that different companies (same business nature, but different product) had their distinctive ways in developing the process flow of the approved supplier list. The results can be used as reference to other companies to restructure their process flow for approved supplier list; focusing on their business goal and objective
